Conference Focused on the Future of HEOR
New Orleans, LA, USA—May 23, 2019—ISPOR, the professional
society for health economics and outcomes research (HEOR), recently concluded
its ISPOR
2019 annual
conference in New Orleans, LA, USA. The conference convened nearly 4000 healthcare
stakeholders representing more than 65 countries and from all sectors of
healthcare, including policy makers, global thought leaders, researchers and
academicians, public and private payers, healthcare providers, and patient engagement
organizations. The conference centered on the timely theme, “Rapid. Disruptive.
Innovative. A New Era in HEOR,” and addressed a wide variety of compelling
topics in HEOR.
The conference opened with the keynote and first
plenary session, “The
Dawn of Disruption in the Health Sector: Will Innovative Technologies Require
Innovative Thinking?” The keynote was
delivered by Daniel Kraft, MD, faculty chair for medicine, Singularity
University, founder and chair, Exponential Medicine, Stanford, CA, USA. His
keynote explored the impact of disruptive medical therapies on medicine today
and into the future, setting the stage for the plenary session. The plenary session panel examined
the impact, challenges, and opportunities of the recent renaissance of
groundbreaking, new, curative health technologies and included Clifford
Goodman, PhD, The Lewin Group, Falls Church, VA, USA who moderated; Timothy
Caulfield, LLM, University of Alberta, Edmonton, AB, Canada; Fleur Chandler,
Patient Advisory Board, Duchenne, Twickenham, England, UK; Alexander Billioux,
MD, PhD, Louisiana Department of Health, Baton Rouge, LA, USA; and Ron Philip,
Spark Therapeutics, Inc, Philadelphia, PA, USA. Dr Kraft joined the panel for
the question and answer session.
The second plenary, “Medical
Device Innovation and Regulation: Turbocharged for Success?” explored ways that
regulators can ensure a high level of health protection while also allowing for
research and growth in the sector. Panelists included Laurie Burke, MPH, LORA
Group LLC and University of Maryland School of Pharmacy, Royal Oak, MD, USA who
moderated the session; Stephanie Christopher, MA, Medical Device Innovation
Consortium, Arlington, VA, USA; Paul Coplan, ScD, MBA, Johnson and Johnson, New
Brunswick, NJ, USA; Stephen A. Hull, MHS, Hull Associates LLC, Rockland, MA,
USA; and Harindra Wijeysundera, MD, PhD, Canadian Agency for Drugs and
Technologies in Health, Ottawa, ON,
Canada.
The third plenary, “Is
Healthcare Affordability Driving a Need to Revolutionize Drug Pricing?,” examined
the issue of drug pricing in the United States with moderator Colleen M. Flood;
University of Ottawa Centre for Health Law, Policy and Ethics; Ottawa, ON,
Canada and panelists Muna Bhanji, RPh, Merck, Philadelphia, PA, USA; Meindert
Boysen, PharmD, MSc, National Institute for Health and Care Excellence, Manchester,
England, UK; Louis P. Garrison, Jr, PhD, University of Washington, Seattle, WA,
USA; and Mark Trusheim, MS, NEWDIGS and Massachusetts Institute of Technology, Cambridge,
MA, USA.
ISPOR 2019 also hosted a variety of sessions on topics
that included, orphan
drugs and the challenges they pose to health plans, the
future of HEOR, real-world
evidence and patient-provided information, how
formal health technology assessment could help solve the United States’ high healthcare
costs, and patients’
access to biosimilars. ISPOR held its first Annual
Awards Banquet to honor the 2019 HEOR Scientific and Leadership Awards
winners. The Society’s journal, Value in
Health released its 20th
anniversary issue featuring the publication’s new “look” and held a special
spotlight
session at the conference with the founding and current editors-in-chief taking
a retrospective look at the journal. And ISPOR’s Women
in HEOR initiative held a session on mentorship and thought leadership at
the conference.
ISPOR CEO and Executive Director Nancy S. Berg stated,
“Our ISPOR 2019 annual conference convened HEOR leaders from around the world
to discuss the new emerging era in health economics and outcomes research and
to reimagine HEOR. The focus on disruption and innovation in the field will
help shape the future of HEOR and aligns with the Society’s mission to improve
healthcare decisions.”
ISPOR is recognized globally as the leading
professional society for health economics and outcomes research and its role in
improving healthcare decisions. ISPOR 2019 is the leading global HEOR
conference and draws nearly 4000 healthcare thought leaders and stakeholders,
including researchers and academicians, assessors and regulators, payers and
policy makers, the life sciences industry, healthcare providers, and patient
engagement organizations.
Additional information on the conference can be found at:
Conference Information | Program | Sponsors | Exhibitors | Press
###
ABOUT
ISPOR
ISPOR, the professional society for health economics
and outcomes research (HEOR), is an international, multistakeholder, nonprofit
dedicated to advancing HEOR excellence to improve decision making for health
globally. The Society is the leading source for scientific conferences,
peer-reviewed and MEDLINE®-indexed publications, good practices guidance,
education, collaboration, and tools/resources in the field.
Web: www.ispor.org | LinkedIn: www.linkedin.com/company/ispororg | Twitter: www.twitter.com/ispororg (@ISPORorg) | YouTube: www.youtube.com/ispororg | Facebook: www.facebook.com/ispororg | Instagram: www.instagram.com/ispororg